<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Topical agents and dressings for local burn wound care</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Topical agents and dressings for local burn wound care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Topical agents and dressings for local burn wound care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mayer Tenenhaus, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hans-Oliver Rennekampff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc G Jeschke, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21593871"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Local treatment of burn wounds includes cleansing and debridement and routine burn wound dressing changes, typically incorporating topical antimicrobial agents; however, there is no consensus on which agent or dressing is optimal for burn wound coverage to prevent or control infection or to enhance wound healing [<a href="#rid1">1,2</a>].</p><p>The selection and application of burn wound dressings and topical agents depends on the nature and extent of the burn wound, a particular wound quality or state (eg, contamination, infection), and the patient's allergy history. The dressings and topical therapies that are used at a given facility depend upon regional and individual preference and experience, availability, and costs. </p><p>The most frequently used burn wound dressings and topical agents in adults and children will be reviewed here. The classification and management of burns by depth of burn and the specialized management of burns at specific anatomic sites are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/819.html" rel="external">"Assessment and classification of burn injury"</a> and  <a class="medical medical_review" href="/z/d/html/349.html" rel="external">"Treatment of minor thermal burns"</a> and  <a class="medical medical_review" href="/z/d/html/114176.html" rel="external">"Treatment of superficial burns requiring hospital admission"</a> and  <a class="medical medical_review" href="/z/d/html/114178.html" rel="external">"Treatment of deep burns"</a>.)</p><p class="headingAnchor" id="H909959000"><span class="h1">LOCAL BURN WOUND CARE</span></p><p class="headingAnchor" id="H1843043934"><span class="h2">Goals</span><span class="headingEndMark"> — </span>Local burn wound care  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60931" href="/z/d/graphic/60931.html" rel="external">table 2</a>) aims to protect the wound surface, maintain a moist environment, promote burn wound healing, and limit burn wound progression while minimizing discomfort for the patient [<a href="#rid3">3</a>]. It is important to note that topical antimicrobials are used in conjunction with appropriate basic wound care. (See  <a class="medical medical_review" href="/z/d/html/15912.html" rel="external">"Basic principles of wound management"</a>.)</p><p>Burn wound surfaces are prone to rapid bacterial colonization with the potential for invasive infection. Measures to reduce the likelihood of infection include good infection control practices, topical antimicrobial therapy, and burn wound debridement/excision, when needed [<a href="#rid4">4</a>]. Closed dressing management is often advocated to minimize cross-contamination by pathogens (eg, methicillin-resistant <em>Staphylococcus aureus</em>)<em> </em>that can cause burn wound infection, delayed wound healing, and loss of skin grafts [<a href="#rid5">5</a>]. Wounds that become infected require systemic antimicrobial therapy, in addition to the chosen regimen for local wound care. (See  <a class="medical medical_review" href="/z/d/html/14985.html" rel="external">"Burn wound infection and sepsis"</a>.)</p><p class="headingAnchor" id="H2088109107"><span class="h2">Dressings</span><span class="headingEndMark"> — </span>A variety of antimicrobial agents (see <a class="local">'Antimicrobial agents'</a> below) can be applied to the burn wound surface, which is then covered with one of several dressing materials (eg, gauze, nonadherent films)  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60931" href="/z/d/graphic/60931.html" rel="external">table 2</a>). </p><p>Early after injury, it may be difficult to accurately determine the depth of burn wounds, and, since burn wounds are often of mixed depths, more than one local wound care regimen may be necessary. Our approach to local burn wound care based on burn wound depth  (<a class="graphic graphic_table graphicRef61540" href="/z/d/graphic/61540.html" rel="external">table 3</a>) is summarized briefly below and discussed in more depth elsewhere. (See <a class="local">'Efficacy and use of topical therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/114176.html" rel="external">"Treatment of superficial burns requiring hospital admission"</a> and  <a class="medical medical_review" href="/z/d/html/114178.html" rel="external">"Treatment of deep burns"</a>.)</p><p>Gauze alone should be avoided unless there are no other options (ie, topical antimicrobials are not available). Dry gauze promotes scab formation, which will generally separate spontaneously as reepithelialization occurs. However, pain can be significant when the gauze is removed. </p><p>Nonadherent films or fine mesh gauze (in combination with topical antimicrobials) are common dressings used to cover the burn wound, but films, foams, alginates, hydrocolloids, and hydrogels can also be used depending on the specific qualities of the dressing (eg, silver containing) and the specific needs of the burn wound. These can either cover a burn wound treated with a topical agent or be applied directly to the wound. As examples, partial-thickness burns have moderate-to-high amounts of exudate, which are appropriately managed with foams and alginates. By comparison, for a graft donor site that has minimal-to-moderate exudate, the use of polyurethane, hydrocolloids, or hydrogels may be adequate. </p><p>Coverage of clean, uninfected burn wounds can also be accomplished using biologic dressings or skin substitutes. These are applied once and adhere to the wound, separating spontaneously as healing progresses [<a href="#rid6">6</a>]. (See <a class="local">'Temporary burn wound coverage'</a> below.) </p><p>Dressing changes should be frequent enough to control exudate but not so frequent that they interfere with wound reepithelialization. The frequency ranges from twice daily to weekly depending upon the amount of exudate and choice of dressing material. More frequent dressing changes are performed if there is a large amount of exudate, weeping, or infection [<a href="#rid7">7</a>]. </p><p>Topical antimicrobials should be gently removed with dressing changes. Excessive scrubbing and sharp debridement is not necessary and may hinder healing. Management of pain in association with burn wound care is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114176.html" rel="external">"Treatment of superficial burns requiring hospital admission", section on 'Pain management'</a> and  <a class="medical medical_review" href="/z/d/html/16505.html" rel="external">"Paradigm-based treatment approaches for management of burn pain", section on 'Procedural pain'</a> and  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching"</a>.)</p><p class="headingAnchor" id="H2130890734"><span class="h1">ANTIMICROBIAL AGENTS</span><span class="headingEndMark"> — </span>Commonly used topical agents include combination antimicrobial ointments, <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a>, bismuth-impregnated petroleum gauze, <a class="drug drug_general" data-topicid="9579" href="/z/d/drug information/9579.html" rel="external">mafenide</a>, and <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> [<a href="#rid1">1,2,8,9</a>]. Other agents such as honey, povidone-iodine, and Dakin's solution are less commonly used. Combinations of antimicrobials with topical antifungal agents have also demonstrated some efficacy for the local treatment of burns [<a href="#rid10">10</a>]. </p><p>Some of the agents have variable degrees of local or systemic adverse effects and may impede wound healing  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a>) [<a href="#rid1">1,4,11</a>]. However, there is no official standard for testing the efficacy and cytotoxicity of topical antimicrobial agents [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H548352833"><span class="h2">Commonly used agents</span><span class="headingEndMark"> — </span>Commonly used topical agents for partial-thickness burns include antimicrobial ointments, silver-containing agents, bismuth-impregnated petroleum gauze, <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>, and <a class="drug drug_general" data-topicid="9579" href="/z/d/drug information/9579.html" rel="external">mafenide</a> [<a href="#rid8">8,9</a>]. </p><p class="headingAnchor" id="H1620637139"><span class="h3">Antimicrobial ointments</span><span class="headingEndMark"> — </span>Topical antimicrobial ointments (as single agents or combination agents) are commonly used for superficial burn wounds. Compared with <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a>, the advantages of these are ease of application and of removal for wound cleansing. In addition, these can be used in areas of sensitivity, such as on the face, ears, and perineum  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a>).</p><p>Polysporin is a combination of <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">bacitracin</a> zinc and <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">polymyxin B</a> sulfate. It can be used to treat partial-thickness burns, particularly those that involve the face and perineum [<a href="#rid9">9</a>]. For uncomplicated wounds, many clinicians apply Polysporin ointment covered by a nonadherent dressing. However, its efficacy in the treatment of infected wounds has not been clearly established. In the setting of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> ointment/cream is effective [<a href="#rid13">13</a>]. Areas near the eyes are generally managed with ophthalmic derivatives, such as <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a> or <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> ophthalmic ointment. Otherwise, the use of neomycin is generally limited to smaller burn areas. It is frequently mixed (diluted) with bacitracin and polymyxin to reduce absorption [<a href="#rid9">9</a>]. </p><p><a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">Bacitracin</a>, <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a>, and <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">polymyxin B</a> have negligible systemic absorption after topical administration except when applied to large areas or for long periods of time. Polymyxin B has little absorption even when applied to open wounds. However, systemic absorption has been reported when bacitracin, neomycin, or <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> has been applied to damaged epithelium [<a href="#rid14">14</a>]. If absorbed systemically, bacitracin, neomycin, or polymyxin B can cause nephrotoxicity and neurotoxicity. Caution should be used in patients with impaired renal function and in those taking additional medications with nephrotoxic or neurotoxic adverse effects. An alternative is to limit the duration of use and/or to alternate with topical agents that are not absorbed. </p><p class="headingAnchor" id="H2057033169"><span class="h3">Silver-containing agents</span><span class="headingEndMark"> — </span>Silver-containing agents slowly release ionic silver into the wound  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a>). Activated silver has broad-spectrum antimicrobial activity and may also have an anti-inflammatory benefit [<a href="#rid15">15</a>]. There are several silver-containing preparations and dressings, including <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a>, nanocrystalline silver (eg, Acticoat, Aquacel Ag), and <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a>, each of which has its own management requirements. Silver formulations that contain silver nitrate and silver sulfadiazine require more frequent dressing changes. </p><p class="headingAnchor" id="H21593935"><span class="h4">Silver sulfadiazine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">Silver sulfadiazine</a> cream (SSD 1%) applied and covered with fine mesh gauze is the most commonly used burn wound dressing [<a href="#rid1">1</a>]. SSD is widely available and relatively inexpensive and continues to be used in many burn centers as the standard of care for the treatment of burn wounds, with a long history and experience with its use. </p><p>SSD has antimicrobial activity as demonstrated by decreased colonization of burn wounds. However, there are no well-designed trials to confirm improved wound healing or a reduced rate of bacterial wound infection [<a href="#rid1">1,16</a>]. For wounds covering more than 50 to 60 percent of the total body surface area, SSD does not consistently prevent or suppress bacterial growth, particularly of gram-negative bacteria [<a href="#rid17">17</a>]. In addition, there are potential adverse effects. As an example, SSD will form a pseudoeschar that is loose at the edges, which can promote bacterial proliferation. The pseudoeschar requires removal or debridement to improve the ability to monitor the wound state and facilitate reepithelialization. SSD also impedes reepithelialization; as a result, SSD should be stopped when there is evidence of reepithelialization [<a href="#rid1">1</a>].</p><p>SSD is a thick white cream that is applied once or twice daily and can be soothing. SSD and related agents should <strong>not</strong> be used in women who are pregnant or breastfeeding or in infants younger than two months old [<a href="#rid18">18</a>]. SSD is also oculotoxic and should not be used near the eyes [<a href="#rid19">19</a>]. </p><p>Cerium nitrate, one of the lanthanide rare earth elements, can be added to SSD for burns not undergoing immediate excision and closure [<a href="#rid17">17,20-22</a>]. Reports in adult and pediatric burn populations have been conflicting regarding the clinical value of cerium as measured by mortality, length of hospital stay, and bacterial colonization of the wounds. In two trials in the Cochrane review, there were fewer deaths in groups treated with cerium nitrate plus SSD compared with SSD alone (relative risk [RR] 0.22, 95% CI 0.05-0.99 [<a href="#rid20">20,23</a>]). Other studies that did not address these clinical outcomes have found that SSD-cerium was not more effective than SSD alone in reducing burn wound colonization [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H2305651623"><span class="h4">Nanocrystalline silver</span><span class="headingEndMark"> — </span>Nanocrystalline silver dressings are composed of a urethane film embedded with elemental silver that provides sustained release of silver into the wound. Compared with older silver formulations, it has stronger antimicrobial activity and longer-lasting properties that reduce dressing change frequency to weekly, depending upon the amount of exudate [<a href="#rid26">26</a>]. Some nanocrystalline silver dressings (eg, Acticoat) require frequent moistening with water to maintain activation. </p><p>In a systematic review, compared with SSD, nanocrystalline silver had a lower incidence of infection (9.5 versus 27.8 percent, odds ratio 0.14, 95% CI 0.06-0.35) [<a href="#rid27">27</a>]. Nanocrystalline silver was also associated with less pain during change of dressings and lower cost. </p><p>In a trial comparing Acticoat with Allevyn (an occlusive moist-healing environment material), skin graft donor sites dressed with Allevyn reepithelialized at a faster rate [<a href="#rid28">28</a>]. The opposite effect was found in another trial in which wounds treated with Acticoat reepithelialized faster with better comfort compared with Allevyn [<a href="#rid29">29</a>]. Both studies agreed that there was no difference in bacterial colonization of the donor site. </p><p class="headingAnchor" id="H1960138656"><span class="h3">Bismuth-impregnated petroleum gauze</span><span class="headingEndMark"> — </span>Bismuth-impregnated petroleum-based gauze is comparable to other topical antimicrobial agents [<a href="#rid30">30,31</a>]. Bismuth-impregnated gauze is an often preferred dressing for skin graft donor sites and for covering fresh skin grafts, and it is also an excellent option for very small superficial partial-thickness burns where clinical judgment indicates antimicrobial activity is necessary. </p><p>Bismuth-impregnated gauze is applied as a single layer over the burn and then covered with a bulky dressing [<a href="#rid18">18</a>]. The dressing will separate from the wound when it has reepithelialized. Bismuth-impregnated petroleum gauze is particularly useful in children as it is applied only once, decreasing the pain that typically accompanies wound dressing changes. </p><p class="headingAnchor" id="H611021596"><span class="h3">Mafenide acetate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9579" href="/z/d/drug information/9579.html" rel="external">Mafenide</a> acetate  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a>), a potent carbonic anhydrase inhibitor, is an alternative to SSD and may be useful for treating patients with dense bacterial proliferation of the burn wound [<a href="#rid32">32-36</a>]. In a study of 669 burn patients treated with 5% mafenide solution as either the initial topical antimicrobial agent (276 patients) or for chronic treatment, effective activity was achieved, and only 1 percent experienced pain severe enough to discontinue therapy [<a href="#rid36">36</a>]. There was a very low incidence of rash and pruritus and no cases of metabolic acidosis. </p><p><a class="drug drug_general" data-topicid="9579" href="/z/d/drug information/9579.html" rel="external">Mafenide</a> acetate can also be applied as a cream applied once or twice daily at a thickness of approximately 1/16 of an inch [<a href="#rid37">37</a>]. Treatment is typically continued until the burn site is healed or ready for skin grafting.</p><p>Adverse reactions associated with use of <a class="drug drug_general" data-topicid="9579" href="/z/d/drug information/9579.html" rel="external">mafenide</a> include metabolic acidosis, allergic reactions (eg, rash, pruritus, hives, erythema, eosinophilia), and respiratory complications (eg, tachypnea, decrease in arterial pCO<sub>2</sub>)<sub> </sub>[<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H767127719"><span class="h3">Chlorhexidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">Chlorhexidine</a> gluconate  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a>), a long-lasting antimicrobial skin cleanser, is often used with a gauze dressing for burn wound coverage in superficial partial-thickness burns. Chlorhexidine dressings do not interfere with wound reepithelialization, in contrast to <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a> [<a href="#rid1">1</a>]. A combination preparation of silver sulfadiazine and chlorhexidine gluconate has also been used [<a href="#rid40">40,41</a>]. </p><p class="headingAnchor" id="H3731547862"><span class="h2">Others</span></p><p class="headingAnchor" id="H1122628"><span class="h3">Honey</span><span class="headingEndMark"> — </span>Honey-derived wound care dressings heal limited superficial partial-thickness wounds as well as, or better than, several other conventional treatment options such as polyurethane film, paraffin gauze, Soframycin-impregnated gauze, sterile linen, or leaving the burns exposed [<a href="#rid42">42,43</a>]. However, the safety, efficacy, and use of honey-based dressings for the treatment for more severe, extensive, or complex thermal injury has not been established.</p><p>There are few high-quality studies, but evidence from low-quality studies and anecdotal reports in burn patients suggest that honey-derived wound care dressings are generally well tolerated and may show adjunctive efficacy in the treatment of a variety of wound types [<a href="#rid1">1</a>]. In a systematic review comparing honey dressings with <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a>, honey improved healing time (mean difference [MD] -5.76 days, 95% CI -8.14 to -3.39) and the proportion of infected wounds rendered sterile (RR 2.59, 95% CI 1.58-2.88) [<a href="#rid43">43</a>]. An earlier systematic review similarly supported the use of honey in burn wound care while noting the generally low methodologic quality of the available randomized trials [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H1029999210"><span class="h3">Povidone-iodine</span><span class="headingEndMark"> — </span>Povidone-iodine ointment, including a liposomal preparation, effectively combines antimicrobial therapy with a desired moist wound environment. Despite a broad spectrum of antimicrobial activity [<a href="#rid45">45,46</a>], use of povidone-iodine-containing products in burn care is controversial because of cytotoxicity and delay in wound reepithelialization [<a href="#rid11">11,45,47</a>]. Another drawback to povidone-iodine ointment compared with other topical agents is that it must be applied four times a day for maximal antimicrobial effect.</p><p class="headingAnchor" id="H10128208"><span class="h3">Dakin's solution</span><span class="headingEndMark"> — </span>Dakin's solution (0.025% sodium hypochlorite) is widely used in a variety of difficult wound types and has been advocated by some for the management of burn wounds. It has broad-spectrum antimicrobial activity with efficacy in the clinical setting of MRSA, Vancomycin-resistant <em>Enterococcus </em>(VRE), and other antibiotic-resistant bacteria [<a href="#rid48">48</a>]. </p><p>Proponents of Dakin's solution note its broad spectrum of action, minimal cost, and cytoprotective benefits (little impact on fibroblast function). While there are few well-defined papers to strongly advocate its use in burns, it may hold promise, particularly in settings where funding and availability of other standard dressing regimens are lacking. Pain control issues have been noted [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H1886829285"><span class="h1">DEBRIDING AGENTS</span><span class="headingEndMark"> — </span>Enzymatic debriding agents and proteolytics have been successfully used for the early management of deeper and indeterminate depth surgical burn wounds and eschar for many years [<a href="#rid49">49-55</a>]. The aim of using these agents is expedited debridement while affording a measure of specificity and dermal preservation. Products have included <a class="drug drug_general" data-topicid="16759" href="/z/d/drug information/16759.html" rel="external">collagenase</a> derivatives, a variety of fruit enzyme derivatives such as the papain/urea derivatives, as well as bromelain derivatives. The later generation of products have demonstrated greater specificity to eschar. One bromelain derivative, <a class="drug drug_general" data-topicid="140417" href="/z/d/drug information/140417.html" rel="external">anacaulase</a> (NexoBrid), has been granted approval for use in the United States [<a href="#rid49">49</a>], European Union [<a href="#rid56">56</a>], other international markets for the treatment of small- to moderate-sized intermediate and deep dermal thickness burn wounds. Cautions include attention to potential bleeding risk, allergies, as well as adequate analgesia.</p><p class="headingAnchor" id="H321700557"><span class="h1">TEMPORARY BURN WOUND COVERAGE</span></p><p class="headingAnchor" id="H3396221976"><span class="h2">Biologic grafts</span><span class="headingEndMark"> — </span>Biologic graft materials that can be used for temporary coverage of burn wounds include allografts, xenografts, and others (eg, human amnion). These help promote healing or can serve as a bridge to definitive burn wound coverage. Skin autografts and the use of dermal generation templates for permanent coverage for burn wounds are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14990.html" rel="external">"Overview of surgical procedures used in the management of burn injuries"</a> and  <a class="medical medical_review" href="/z/d/html/15118.html" rel="external">"Skin autografting"</a>.)</p><p>Biologic grafts can be used on clean burn wounds, and they protect the wound from desiccation while promoting reepithelialization. The graft separates from the wound once it has reepithelialized. Biologic grafts are especially useful in children as they are applied only once, decreasing the pain that typically accompanies wound dressing changes. </p><p class="bulletIndent1"><span class="glyph">●</span>Allografts – Transient physiologic coverage can be achieved by allogeneic skin grafts (eg, from a nongenetically identical donor from the same species, also called homograft). Allografts are distributed as either fresh or cryopreserved after glycerol preservation from cadavers. The application of an allograft over superficial partial-thickness wounds can minimize pain and facilitate reepithelialization. Allogeneic skin is generally used only in burn centers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Xenografts – Xenografts are generally readily available but may not be as effective as allografts. Skin xenografts, obtained from an unrelated species (heterografts), are used as temporary skin coverage, especially for large burn wounds. Various animal skins have been used in the past, but only porcine grafts are currently used [<a href="#rid57">57,58</a>]. Porcine-derived xenografts do not vascularize but will adhere to a clean superficial wound, accelerate reepithelialization, and reduce pain. Xenografts are easier and cheaper to produce, and more readily available, but are not as effective as allografts. Large-dimensional sheets can be processed, facilitating coverage. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human amnion – Human amniotic membrane has been successfully used as a biologic dressing for partial-thickness wounds [<a href="#rid59">59,60</a>]. However, concerns regarding pathogenic transmission have limited its use. In a retrospective review of 31 studies, amniotic membrane promoted reepithelialization of the burn wound; had antimicrobial properties; and reduced pain, fluid loss, and scar formation. An allograft consisting of sterilized, dehydrated human amnion/chorion membrane (dHACM) has also been used for burn patients [<a href="#rid61">61</a>]. dHACM contains growth factors that promote wound healing, including platelet-derived growth factor A and B, basic fibroblastic growth factor, and transforming growth factor beta 1, and it is stable at ambient temperatures for five years [<a href="#rid62">62,63</a>].</p><p></p><p class="headingAnchor" id="H21594043"><span class="h2">Semibiologic skin substitutes</span><span class="headingEndMark"> — </span>Semibiologic skin substitutes are temporary biosynthetic dressings that are meant to reduce the number of dressing changes and facilitate healing [<a href="#rid60">60</a>]. The semipermeable nature of these dressings allows wound exudate to be absorbed by the external bulky dressing. The type of skin substitute chosen depends upon the appearance of the wound, desired outcome, clinician experience, availability, cost, and cultural preferences, as some are porcine derived. (See  <a class="medical medical_review" href="/z/d/html/118064.html" rel="external">"Skin substitutes"</a>.)</p><p class="headingAnchor" id="H3372169604"><span class="h3">Biobrane and Biobrane-like</span><span class="headingEndMark"> — </span>Biobrane is used to cover donor sites and aid in coverage of large surface area burns, including hands, feet, and joints [<a href="#rid64">64-74</a>]. Biobrane is sometimes used on full-thickness excisions as a temporary covering to protect the excised wound site in a staged fashion prior to subsequent stage skin grafting. (See  <a class="medical medical_review" href="/z/d/html/114178.html" rel="external">"Treatment of deep burns"</a> and  <a class="medical medical_review" href="/z/d/html/16320.html" rel="external">"Overview of the management of the severely burned patient"</a>.)</p><p>Biobrane is a bilaminate membrane that contains a thin semipermeable silicone membrane bonded to a layer of nylon fabric mesh and coated with a monomolecular layer of type 1 porcine collagen [<a href="#rid64">64</a>]. The porcine collagen provides a hydrophilic coating for fibrin growth that promotes wound adherence. Biobrane has no inherent antimicrobial activity, but the membrane is porous, allowing absorption of topical antimicrobial agents and drainage of exudate. Biobrane is versatile and has additional properties of flexibility, elasticity, and transparency for wound observation. </p><p>Some biosynthetic dressings incorporate Biobrane or are of a similar nature, including Transcyte (neonatal fibroblast incorporated into Biobrane), Suprathel (resorbable caprolactone-based materials), and Omiderm (hydrophilized polyurethane membrane). AWBAT, a derivative of Biobrane, is a porous silicone-nylon membrane coated with porcine type 1 collagen [<a href="#rid68">68</a>]. The collagen is not cross-linked to the silicone membrane, which should allow for fibrin in the wound to achieve clotting and improve acute adherence, and the porosity is increased, which should reduce the fluid accumulation and the fluid pressure on the wound. Small trials have confirmed good usability, but whether its anticipated benefits relative to Biobrane will be realized is uncertain [<a href="#rid69">69,75,76</a>]. In a Cochrane review (see <a class="local">'Efficacy and use of topical therapy'</a> below), 10 trials compared the effectiveness of Biobrane or Transcyte to <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a> or other dressings [<a href="#rid1">1</a>]. Overall, biosynthetic dressings resulted in a shorter time to healing, improved pain relief during dressing changes, had lower pain medication requirements, and resulted in a shorter length of hospital stay. </p><p>Biobrane is applied by gently stretching the fabric over the burn surface to avoid wrinkles and is secured to nonburned skin with paper strips [<a href="#rid65">65</a>]. Dry gauze is used to cover the Biobrane, and the dressings are secured with an elastic bandage. The external dressings are changed every 24 hours, and any fluid accumulating under the Biobrane is aspirated. Biobrane can be left in place for up to 14 days, then removed in a warm bath or trimmed. Healed wounds are treated with topical agents or creams. If there is evidence of a wound infection, the Biobrane is removed and the burn treated with topical antimicrobials. (See <a class="local">'Antimicrobial agents'</a> above.) </p><p>Suprathel is applied to the wound after debridement and covered with a layer of fatty gauze. A secondary dressing with cotton gauze is applied. Suprathel and the fatty gauze remain on the wound surface until healing is complete and will separate from the re-epithelialized surface [<a href="#rid66">66,67</a>]. A systematic review of 14 publications related to the use of the Suprathel for donor sites and the treatment of partial thickness burns concluded that while results regarding safety, efficacy, and ease of use are desirable, the cost and a lack of economic assessment is a major limitation for establishing recommendations for use [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H2282759634"><span class="h1">EFFICACY AND USE OF TOPICAL THERAPY</span><span class="headingEndMark"> — </span>Aggressive wound care that includes topical agents with antimicrobial activity has been associated with a reduced incidence of invasive wound infections [<a href="#rid78">78,79</a>], but the efficacy of topical therapy has not been definitively proven [<a href="#rid1">1,7</a>]. In addition, there is no consensus on which agent or dressing is optimal for managing burn wounds to prevent or control infection or enhance wound healing. The various agents are described above. (See <a class="local">'Antimicrobial agents'</a> above.)</p><p>Many randomized trials have compared the various topical agents for the treatment of burn wounds, but most are methodologically poor [<a href="#rid1">1,2,9</a>]. A meta-analysis of randomized trials concerning the topical treatment of facial burns failed to identify any specific treatment that significantly made a difference with respect to outcomes that included wound infection, scar quality, pain, and patient satisfaction [<a href="#rid80">80</a>]. A large systematic review included 56 trials with over 5800 mostly adult patients with partial-thickness burns involving less than 40 percent total body surface area (TBSA) [<a href="#rid1">1</a>]. Most studies compared a given topical agent or dressing with <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a> (SSD). Other comparisons included alternative silver-based agents or dressings, iodine-based agents, <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>, polyhexanide, sodium hypochlorite, merbromin, ethacridine lactate, cerium nitrate, honey, aloe vera, and <em>Arnebia euchroma</em>. It is important to note that most comparisons did not report data on infection, which is an important clinical outcome. </p><p>The main results of this review for the treatment of superficial burns, and those of other reviews, are summarized:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Silver versus non-silver agents</strong> – Several systematic reviews have compared various silver preparations with non-silver-containing dressings [<a href="#rid1">1,16,28,81,82</a>]. These have largely concluded that the evidence is not sufficient to establish whether silver-containing agents or dressings promote wound healing or prevent wound infection. One of these reviews suggested that there may be a detrimental effect from some <a class="drug drug_general" data-topicid="98757" href="/z/d/drug information/98757.html" rel="external">silver-containing dressings</a> [<a href="#rid82">82</a>]. </p><p></p><p class="bulletIndent1">In the Cochrane review, burns treated with nanocrystalline silver dressings had a shorter mean time to healing compared with Vaseline gauze (mean difference [MD] -3.49 days, 95% CI -4.46 to -2.52). There was some evidence that burns treated with honey were more likely to heal over time compared with topical antimicrobials. (See <a class="local">'Honey'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Silver formulation comparison</strong> – There was no difference in the chance of healing over time comparing SSD with other silver-based agents, although other silver-based agents may have increased the number of healing events over 21- or 28-day follow-up and may slightly reduce mean time to healing [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">In a meta-analysis of five clinical trials comparing nanocrystalline silver dressings with older silver formulation dressings (<a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a> and <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a>), the nanocrystalline silver group had a significantly lower rate of infections (9.5 versus 27.8 percent), decreased pain, no clear effect on hospital length of stay, and a higher cost per patient [<a href="#rid27">27</a>]. Other silver formulations (eg, Mepilex Ag) have not demonstrated differences in wound healing but have reduced numbers of dressings and lower cost compared with SSD [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-silver agent comparisons</strong> – In the Cochrane review, there were no clear differences for comparisons between most of the agents [<a href="#rid1">1</a>]. Compared with <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>, wounds treated with povidone-iodine had a reduced mean time to healing (MD -2.21 days, 95% CI 0.34-4.08). </p><p></p><p>Whether the use of specialized dressings (eg, biologic dressings/skin substitutes) improves superficial burn wound outcomes is also uncertain. A systematic review that included 30 randomized trials (most with methodologic shortcomings) did not identify an optimal dressing type [<a href="#rid2">2</a>]. A separate review of 20 trials noted that skin substitutes were at least as effective as topical agents and wound dressings or allografts for the management of partial-thickness burns [<a href="#rid84">84</a>]. For younger patients, biologic substitutes may provide optimal coverage for superficial burns. In a review of 51 observational studies and randomized trials performed in children, biologic dressings (eg, Biobrane, DuoDerm, amnion membrane) showed better results for eschar formation, length of hospital stay, healing time, and pain scores when compared with SSD [<a href="#rid40">40</a>]. (See <a class="local">'Temporary burn wound coverage'</a> above.)</p><p class="headingAnchor" id="H1506166085"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Our approach to local burn wound is summarized and discussed in more depth in the linked topics.</p><p class="headingAnchor" id="H1239828866"><span class="h3">Superficial burn wounds</span><span class="headingEndMark"> — </span>Superficial burn wounds (superficial [epidermal], superficial partial thickness) are covered with dressing materials that aid with skin healing and reepithelialization. In general, superficial burns do not require antimicrobial therapy, but for extensive superficial burns, topical antimicrobials may be used to prevent colonization while maintaining a moist wound healing environment. Furthermore, because superficial partial-thickness burns may not always be easily distinguished from deeper injuries, topical antimicrobial agents are often used. We generally start with a combination antimicrobial ointment or creme (eg, Polysporin) covered with a nonadherent dressing (eg, Xeroform, Adaptic, Mepitel). When in close proximity to the eyes, we use an ophthalmic ointment without steroids. (See  <a class="medical medical_review" href="/z/d/html/114176.html" rel="external">"Treatment of superficial burns requiring hospital admission", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H1020592345"><span class="h3">Deep burn wounds</span><span class="headingEndMark"> — </span>Deep burn wounds (deep partial thickness, full thickness, and deeper) require burn wound excision and graft/flap coverage. The deep burn wound site may often constitute a mixed pattern of injury with differing permeability and compromised barrier function. The role of topical agents at these wound sites is to delay the onset of an invasive infection prior to early surgical excision of nonvital tissue. The challenge is that many of these products hamper the ability of the burn team to evaluate the quality, extent, and depth of injury. As such, prior to definitive care and burn wound excision, a preliminary gauze dressing is often first applied. Excising full-thickness eschar removes the biologic and bacterial burden, decreasing morbidity and mortality while facilitating the efficacy of wound dressings, biologics, biosynthetics, and definitive coverage. Following eschar debridement and/or excision, if grafting will not take place immediately, for interim wound management, fine mesh gauze in combination with topical antimicrobials, typically silver-containing agents or dressings (eg, Silvadene, Sulfamylon, Acticoat), is used to provide a moist and minimally adherent provisional dressing until definitive debridement or surgical excision can be performed. Provisional coverage with allograft, biologics, and biosynthetic is applicable when the wound bed is optimized. Dressings are also used after surgery to cover and protect skin grafts and skin graft donor sites. (See  <a class="medical medical_review" href="/z/d/html/114178.html" rel="external">"Treatment of deep burns"</a> and  <a class="medical medical_review" href="/z/d/html/14990.html" rel="external">"Overview of surgical procedures used in the management of burn injuries"</a>.)</p><p class="headingAnchor" id="H2965139580"><span class="h3">Colonized/contaminated/infected burn wounds</span><span class="headingEndMark"> — </span>When contamination with methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) is suspected/confirmed, directed topical antimicrobial treatment (eg, <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> ointment/cream) should be added as a treatment [<a href="#rid85">85</a>]. Other treatments (eg, <a class="drug drug_general" data-topicid="9579" href="/z/d/drug information/9579.html" rel="external">mafenide</a>) may be more appropriate for heavily colonized or infected burn wounds (in addition to systemic antimicrobial therapy, as indicated). (See <a class="local">'Antimicrobial ointments'</a> above and  <a class="medical medical_review" href="/z/d/html/14985.html" rel="external">"Burn wound infection and sepsis"</a>.)</p><p>Dressings are also used after surgery to cover and protect skin grafts and skin graft donor sites. (See  <a class="medical medical_review" href="/z/d/html/15118.html" rel="external">"Skin autografting", section on 'Recipient site dressings and care'</a> and  <a class="medical medical_review" href="/z/d/html/15118.html" rel="external">"Skin autografting", section on 'Donor site dressings and care'</a>.)</p><p class="headingAnchor" id="H2735885440"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117752.html" rel="external">"Society guideline links: Care of the patient with burn injury"</a>.)</p><p class="headingAnchor" id="H21594261"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals</strong> – Local burn wound care  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60931" href="/z/d/graphic/60931.html" rel="external">table 2</a>) aims to protect the wound surface, maintain a moist environment, promote burn wound healing, and limit burn wound progression while minimizing discomfort for the patient. (See <a class="local">'Goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical antimicrobial agents</strong> – A variety of antimicrobial agents  (<a class="graphic graphic_table graphicRef81801" href="/z/d/graphic/81801.html" rel="external">table 1</a>) can be applied to the burn wound surface, which is then covered using one of several dressing materials. Commonly used topical antimicrobial agents include antimicrobial ointments (alone or in combination), <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a>, bismuth-impregnated petroleum gauze, <a class="drug drug_general" data-topicid="9579" href="/z/d/drug information/9579.html" rel="external">mafenide</a>, and <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>. When contamination with methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) is suspected/confirmed, directed topical antimicrobial treatment (eg, <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> ointment/cream) should be added. Other treatments (eg, mafenide) may be more appropriate for heavily colonized or infected burn wounds (in addition to systemic antimicrobial therapy, as indicated). Silver sulfadiazine, alone or with cerium, and povidone-iodine are contraindicated in burn patients who are pregnant or lactating, and in newborns. (See <a class="local">'Antimicrobial agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dressings</strong> – Nonadherent films or fine mesh gauze (in combination with topical antimicrobials) are common dressings used to cover the burn wound, but other materials (eg, films, foams, alginates, hydrocolloids, and hydrogels  (<a class="graphic graphic_table graphicRef60931" href="/z/d/graphic/60931.html" rel="external">table 2</a>) can also be used depending on the qualities of the dressing and the specific needs of the burn wound. The frequency of dressing changes ranges from twice daily to weekly depending upon the choice of dressing. Dressing changes should be frequent enough to control exudate but not so frequent that they interfere with wound reepithelialization. (See <a class="local">'Dressings'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporary burn wound coverage</strong> – Biologic graft materials and semibiologic skin substitutes can be used for temporary coverage of burn wounds to help promote healing or serve as a bridge to definitive burn wound coverage. Biologic grafts are applied only once; after the wound has reepithelialized, the graft separates from the wound. Biologic grafts are especially useful in children. (See <a class="local">'Temporary burn wound coverage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and use of topical therapy</strong> – Aggressive wound care that includes topical agents with antimicrobial activity has been associated with a reduced incidence of invasive wound infections, but the efficacy of topical therapy has not been definitively proven. In the absence of high-quality data and no consensus, the choice can be made based on cost, availability, frequency of dressing changes, and provider familiarity. We use the following approaches to manage superficial and deep burn wounds. (See <a class="local">'Efficacy and use of topical therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Superficial burn wounds</strong> – Superficial burn wounds (superficial [epidermal], superficial partial thickness) are covered with dressing materials that aid with skin healing and reepithelialization. In general, superficial burns do not require antimicrobial therapy, but for extensive superficial burns, topical antimicrobials may be used to prevent colonization while maintaining a moist wound healing environment. Furthermore, because superficial partial-thickness burns may not always be easily distinguished from deeper injuries, topical antimicrobial agents are often used. We generally start with a combination antibiotic ointment or creme (eg, Polysporin) covered with a nonadherent dressing (eg, Xeroform, Adaptic, Mepitel). When in close proximity to the eyes, we use an ophthalmic ointment without steroids. (See  <a class="medical medical_review" href="/z/d/html/114176.html" rel="external">"Treatment of superficial burns requiring hospital admission", section on 'Our approach'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Deep burn wounds</strong> – Deep burn wounds (deep partial thickness, full thickness, deeper burns) ultimately require burn wound excision and graft/flap coverage. Prior to definitive care and burn wound excision, a preliminary gauze dressing is often first applied. Following eschar debridement and/or excision, if grafting will not take place immediately, for interim wound management, fine mesh gauze in combination with topical antimicrobials, typically silver-containing agents or dressings (eg, Silvadene, Sulfamylon, Acticoat), is often used to provide a moist and minimally adherent provisional dressing. (See  <a class="medical medical_review" href="/z/d/html/114178.html" rel="external">"Treatment of deep burns"</a> and  <a class="medical medical_review" href="/z/d/html/14990.html" rel="external">"Overview of surgical procedures used in the management of burn injuries"</a> and  <a class="medical medical_review" href="/z/d/html/16320.html" rel="external">"Overview of the management of the severely burned patient"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Norman G, Christie J, Liu Z, et al. Antiseptics for burns. Cochrane Database Syst Rev 2017; 7:CD011821.</a></li><li><a class="nounderline abstract_t">Wasiak J, Cleland H, Campbell F, Spinks A. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev 2013; :CD002106.</a></li><li><a class="nounderline abstract_t">Yoshino Y, Ohtsuka M, Kawaguchi M, et al. The wound/burn guidelines - 6: Guidelines for the management of burns. J Dermatol 2016; 43:989.</a></li><li><a class="nounderline abstract_t">D'Avignon LC, Saffle JR, Chung KK, Cancio LC. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008; 64:S277.</a></li><li><a class="nounderline abstract_t">White RJ, Cutting K, Kingsley A. Topical antimicrobials in the control of wound bioburden. Ostomy Wound Manage 2006; 52:26.</a></li><li><a class="nounderline abstract_t">Inoue Y, Hasegawa M, Maekawa T, et al. The wound/burn guidelines - 1: Wounds in general. J Dermatol 2016; 43:357.</a></li><li><a class="nounderline abstract_t">ISBI Practice Guidelines Committee, Steering Subcommittee, Advisory Subcommittee. ISBI Practice Guidelines for Burn Care. Burns 2016; 42:953.</a></li><li><a class="nounderline abstract_t">Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev 2008; :CD002106.</a></li><li><a class="nounderline abstract_t">Palmieri TL, Greenhalgh DG. Topical treatment of pediatric patients with burns: a practical guide. Am J Clin Dermatol 2002; 3:529.</a></li><li><a class="nounderline abstract_t">Neely AN, Gardner J, Durkee P, et al. Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? J Burn Care Res 2009; 30:19.</a></li><li><a class="nounderline abstract_t">Vermeulen H, Westerbos SJ, Ubbink DT. Benefit and harm of iodine in wound care: a systematic review. J Hosp Infect 2010; 76:191.</a></li><li><a class="nounderline abstract_t">Cooper ML, Boyce ST, Hansbrough JF, et al. Cytotoxicity to cultured human keratinocytes of topical antimicrobial agents. J Surg Res 1990; 48:190.</a></li><li><a class="nounderline abstract_t">Hughes J, Mellows G. Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J 1978; 176:305.</a></li><li class="breakAll">http://www.oregon.gov/OHA/pharmacy/therapeutics/docs/ps-2010-03-antibiotics-topical.pdf (Accessed on March 28, 2016).</li><li><a class="nounderline abstract_t">Nadworny PL, Wang J, Tredget EE, Burrell RE. Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis. J Inflamm (Lond) 2010; 7:13.</a></li><li><a class="nounderline abstract_t">Heyneman A, Hoeksema H, Vandekerckhove D, et al. The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: A systematic review. Burns 2016; 42:1377.</a></li><li><a class="nounderline abstract_t">Fox CL Jr, Monafo WW Jr, Ayvazian VH, et al. Topical chemotherapy for burns using cerium salts and silver sulfadiazine. Surg Gynecol Obstet 1977; 144:668.</a></li><li><a class="nounderline abstract_t">Schonfeld N. Outpatient management of burns in children. Pediatr Emerg Care 1990; 6:249.</a></li><li><a class="nounderline abstract_t">Mohan M, Gupta SK, Kalra VK, et al. Topical silver sulphadiazine--a new drug for ocular keratomycosis. Br J Ophthalmol 1988; 72:192.</a></li><li><a class="nounderline abstract_t">de Gracia CG. An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns 2001; 27:67.</a></li><li><a class="nounderline abstract_t">Garner JP, Heppell PS. Cerium nitrate in the management of burns. Burns 2005; 31:539.</a></li><li><a class="nounderline abstract_t">Ross DA, Phipps AJ, Clarke JA. The use of cerium nitrate-silver sulphadiazine as a topical burns dressing. Br J Plast Surg 1993; 46:582.</a></li><li><a class="nounderline abstract_t">Oen IMMH, van Baar ME, Middelkoop E, Nieuwenhuis MK. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns:  a multicenter, randomized, controlled trial. Plast Reconstr Surg 2012; 130:274e.</a></li><li><a class="nounderline abstract_t">Munster AM, Helvig E, Rowland S. Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective evaluation. Surgery 1980; 88:658.</a></li><li><a class="nounderline abstract_t">Bowser BH, Caldwell FT, Cone JB, et al. A prospective analysis of silver sulfadiazine with and without cerium nitrate as a topical agent in the treatment of severely burned children. J Trauma 1981; 21:558.</a></li><li><a class="nounderline abstract_t">Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns 2004; 30 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Gravante G, Caruso R, Sorge R, et al. Nanocrystalline silver: a systematic review of randomized trials conducted on burned patients and an evidence-based assessment of potential advantages over older silver formulations. Ann Plast Surg 2009; 63:201.</a></li><li><a class="nounderline abstract_t">Innes ME, Umraw N, Fish JS, et al. The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study. Burns 2001; 27:621.</a></li><li><a class="nounderline abstract_t">Argirova M, Hadjiski O, Victorova A. Acticoat versus Allevyn as a split-thickness skin graft donor-site dressing: a prospective comparative study. Ann Plast Surg 2007; 59:415.</a></li><li><a class="nounderline abstract_t">Malpass KG, Snelling CF, Tron V. Comparison of donor-site healing under Xeroform and Jelonet dressings: unexpected findings. Plast Reconstr Surg 2003; 112:430.</a></li><li><a class="nounderline abstract_t">Hansbrough W, Doré C, Hansbrough JF. Management of skin-grafted burn wounds with Xeroform and layers of dry coarse-mesh gauze dressing results in excellent graft take and minimal nursing time. J Burn Care Rehabil 1995; 16:531.</a></li><li><a class="nounderline abstract_t">Ibrahim A, Fagan S, Keaney T, et al. A simple cost-saving measure: 2.5% mafenide acetate solution. J Burn Care Res 2014; 35:349.</a></li><li><a class="nounderline abstract_t">Zahmatkesh M, Manesh MJ, Babashahabi R. Effect of Olea ointment and Acetate Mafenide on burn wounds - A randomized clinical trial. Iran J Nurs Midwifery Res 2015; 20:599.</a></li><li><a class="nounderline abstract_t">Studer NM, Driscoll IR, Daly IM, Graybill JC. Care of the Burn Casualty in the Prolonged Field Care Environment. J Spec Oper Med 2015; 15:86.</a></li><li><a class="nounderline abstract_t">Ahuja RB, Gupta A, Gur R. A prospective double-blinded comparative analysis of framycetin and silver sulphadiazine as topical agents for burns: a pilot study. Burns 2009; 35:672.</a></li><li><a class="nounderline abstract_t">Kucan JO, Smoot EC. Five percent mafenide acetate solution in the treatment of thermal injuries. J Burn Care Rehabil 1993; 14:158.</a></li><li class="breakAll">Mafenide acetate cream. www.druginformation.com/RxDrugs/M/Mafenide%20Acetate%20Cream.html (Accessed on June 03, 2014).</li><li><a class="nounderline abstract_t">Haynes BW Jr. Mafenide acetate in burn treatment. N Engl J Med 1971; 284:1324.</a></li><li class="breakAll">Sulfamylon (mafenide acetate) cream. dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9972DB4C-703F-4CBC-915C-EC993BFF6FB9 (Accessed on June 03, 2014).</li><li><a class="nounderline abstract_t">Vloemans AF, Hermans MH, van der Wal MB, et al. Optimal treatment of partial thickness burns in children: a systematic review. Burns 2014; 40:177.</a></li><li><a class="nounderline abstract_t">Inman RJ, Snelling CF, Roberts FJ, et al. Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection. Burns Incl Therm Inj 1984; 11:35.</a></li><li><a class="nounderline abstract_t">Jull AB, Cullum N, Dumville JC, et al. Honey as a topical treatment for wounds. Cochrane Database Syst Rev 2015; :CD005083.</a></li><li><a class="nounderline abstract_t">Aziz Z, Abdul Rasool Hassan B. The effects of honey compared to silver sulfadiazine for the treatment of burns: A systematic review of randomized controlled trials. Burns 2017; 43:50.</a></li><li><a class="nounderline abstract_t">Brölmann FE, Ubbink DT, Nelson EA, et al. Evidence-based decisions for local and systemic wound care. Br J Surg 2012; 99:1172.</a></li><li><a class="nounderline abstract_t">Norman D. The use of povidone-iodine in superficial partial-thickness burns. Br J Nurs 2003; 12:S30.</a></li><li><a class="nounderline abstract_t">Homann HH, Rosbach O, Moll W, et al. A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds. Ann Plast Surg 2007; 59:423.</a></li><li><a class="nounderline abstract_t">Steen M. Review of the use of povidone-iodine (PVP-I) in the treatment of burns. Postgrad Med J 1993; 69 Suppl 3:S84.</a></li><li><a class="nounderline abstract_t">Ahmed N, Shahzad MN, Qureshi KH, et al. Effectiveness of 0.025% dakin's solution versus 1% silver sulphadiazine for treatment of partial thickness burns. Ann Pak Inst Med Sci 2011; 7:127.</a></li><li><a class="nounderline abstract_t">Hirche C, Kreken Almeland S, Dheansa B, et al. Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: European consensus guidelines update. Burns 2020; 46:782.</a></li><li><a class="nounderline abstract_t">Edmondson SJ, Ali Jumabhoy I, Murray A. Time to start putting down the knife: A systematic review of burns excision tools of randomised and non-randomised trials. Burns 2018; 44:1721.</a></li><li><a class="nounderline abstract_t">Rosenberg L, Krieger Y, Bogdanov-Berezovski A, et al. A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns 2014; 40:466.</a></li><li><a class="nounderline abstract_t">Arkoulis N, Mabvuure NT, Smith A, Barnes DE. Early experiences using bromelain-based enzymatic debridement in a tertiary burns centre in the United Kingdom: A retrospective case series review. J Plast Reconstr Aesthet Surg 2021; 74:1402.</a></li><li><a class="nounderline abstract_t">Schulz A, Fuchs PC, Rothermundt I, et al. Enzymatic debridement of deeply burned faces: Healing and early scarring based on tissue preservation compared to traditional surgical debridement. Burns 2017; 43:1233.</a></li><li><a class="nounderline abstract_t">De Decker I, De Graeve L, Hoeksema H, et al. Enzymatic debridement: past, present, and future. Acta Chir Belg 2022; 122:279.</a></li><li><a class="nounderline abstract_t">Shoham Y, Krieger Y, Rubin G, et al. Rapid enzymatic burn debridement: A review of the paediatric clinical trial experience. Int Wound J 2020; 17:1337.</a></li><li class="breakAll">NexoBrid https://www.ema.europa.eu/en/medicines/human/EPAR/nexobrid#authorisation-details-section (Accessed on February 03, 2023).</li><li><a class="nounderline abstract_t">Song IC, Bromberg BE, Mohn MP, Koehnlein E. Heterografts as biological dressings for large skin wounds. Surgery 1966; 59:576.</a></li><li><a class="nounderline abstract_t">Elliott RA Jr, Hoehn JG. Use of commercial porcine skin for wound dressings. Plast Reconstr Surg 1973; 52:401.</a></li><li><a class="nounderline abstract_t">Adly OA, Moghazy AM, Abbas AH, et al. Assessment of amniotic and polyurethane membrane dressings in the treatment of burns. Burns 2010; 36:703.</a></li><li><a class="nounderline abstract_t">Kesting MR, Wolff KD, Hohlweg-Majert B, Steinstraesser L. The role of allogenic amniotic membrane in burn treatment. J Burn Care Res 2008; 29:907.</a></li><li><a class="nounderline abstract_t">Fairbairn NG, Randolph MA, Redmond RW. The clinical applications of human amnion in plastic surgery. J Plast Reconstr Aesthet Surg 2014; 67:662.</a></li><li><a class="nounderline abstract_t">Fetterolf DE, Snyder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds 2012; 24:299.</a></li><li><a class="nounderline abstract_t">Koob TJ, Rennert R, Zabek N, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J 2013; 10:493.</a></li><li><a class="nounderline abstract_t">Whitaker IS, Prowse S, Potokar TS. A critical evaluation of the use of Biobrane as a biologic skin substitute: a versatile tool for the plastic and reconstructive surgeon. Ann Plast Surg 2008; 60:333.</a></li><li><a class="nounderline abstract_t">Lang EM, Eiberg CA, Brandis M, Stark GB. Biobrane in the treatment of burn and scald injuries in children. Ann Plast Surg 2005; 55:485.</a></li><li><a class="nounderline abstract_t">Schwarze H, Küntscher M, Uhlig C, et al. Suprathel, a new skin substitute, in the management of partial-thickness burn wounds: results of a clinical study. Ann Plast Surg 2008; 60:181.</a></li><li><a class="nounderline abstract_t">Hundeshagen G, Collins VN, Wurzer P, et al. A Prospective, Randomized, Controlled Trial Comparing the Outpatient Treatment of Pediatric and Adult Partial-Thickness Burns with Suprathel or Mepilex Ag. J Burn Care Res 2018; 39:261.</a></li><li><a class="nounderline abstract_t">Woodroof EA. The search for an ideal temporary skin substitute: AWBAT. Eplasty 2009; 9:e10.</a></li><li><a class="nounderline abstract_t">Vandenberg VB. AWBAT: early clinical experience. Eplasty 2010; 10:e23.</a></li><li><a class="nounderline abstract_t">Piatkowski A, Drummer N, Andriessen A, et al. Randomized controlled single center study comparing a polyhexanide containing bio-cellulose dressing with silver sulfadiazine cream in partial-thickness dermal burns. Burns 2011; 37:800.</a></li><li><a class="nounderline abstract_t">McHugh TP, Robson MC, Heggers JP, et al. Therapeutic efficacy of Biobrane in partial- and full-thickness thermal injury. Surgery 1986; 100:661.</a></li><li><a class="nounderline abstract_t">Peck MD, Kessler M, Meyer AA, Bonham Morris PA. A trial of the effectiveness of artificial dermis in the treatment of patients with burns greater than 45% total body surface area. J Trauma 2002; 52:971.</a></li><li><a class="nounderline abstract_t">Smith DJ, McHugh TP, Phillips LG, et al. Biosynthetic compound dressings--management of hand burns. Burns Incl Therm Inj 1988; 14:405.</a></li><li><a class="nounderline abstract_t">Frame JD, Taweepoke P, Moieman N, Rylah L. Immediate fascial flap reconstruction of joints and use of Biobrane in the burned limb. Burns 1990; 16:381.</a></li><li><a class="nounderline abstract_t">Solanki NS, Mackie IP, Greenwood JE. A randomised prospective study of split skin graft donor site dressings: AWBAT-D™ vs. Duoderm®. Burns 2012; 38:889.</a></li><li><a class="nounderline abstract_t">Greenwood JE. A Randomized, Prospective Study of the Treatment of Superficial Partial-Thickness Burns: AWBAT-S Versus Biobrane. Eplasty 2011; 11:e10.</a></li><li><a class="nounderline abstract_t">Rahimi F, Rezayatmand R. Use of a biosynthetic wound dressing to treat burns: a systematic review. J Wound Care 2020; 29:S16.</a></li><li><a class="nounderline abstract_t">Pruitt BA Jr, O'Neill JA Jr, Moncrief JA, Lindberg RB. Successful control of burn-wound sepsis. JAMA 1968; 203:1054.</a></li><li><a class="nounderline abstract_t">Brown TP, Cancio LC, McManus AT, Mason AD Jr. Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective. J Trauma 2004; 56:863.</a></li><li><a class="nounderline abstract_t">Hoogewerf CJ, Hop MJ, Nieuwenhuis MK, et al. Topical treatment for facial burns. Cochrane Database Syst Rev 2020; 7:CD008058.</a></li><li><a class="nounderline abstract_t">Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. Cochrane Database Syst Rev 2010; :CD006478.</a></li><li><a class="nounderline abstract_t">Rashaan ZM, Krijnen P, Klamer RR, et al. Nonsilver treatment vs. silver sulfadiazine in treatment of partial-thickness burn wounds in children: a systematic review and meta-analysis. Wound Repair Regen 2014; 22:473.</a></li><li><a class="nounderline abstract_t">Tang H, Lv G, Fu J, et al. An open, parallel, randomized, comparative, multicenter investigation evaluating the efficacy and tolerability of Mepilex Ag versus silver sulfadiazine in the treatment of deep partial-thickness burn injuries. J Trauma Acute Care Surg 2015; 78:1000.</a></li><li><a class="nounderline abstract_t">Pham C, Greenwood J, Cleland H, et al. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 2007; 33:946.</a></li><li><a class="nounderline abstract_t">White RJ, Cooper R, Kingsley A. Wound colonization and infection: the role of topical antimicrobials. Br J Nurs 2001; 10:563.</a></li></ol></div><div id="topicVersionRevision">Topic 13509 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28700086" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antiseptics for burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543513" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Dressings for superficial and partial thickness burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26971391" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The wound/burn guidelines - 6: Guidelines for the management of burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316972" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevention and management of infections associated with burns in the combat casualty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896238" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Topical antimicrobials in the control of wound bioburden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26972819" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The wound/burn guidelines - 1: Wounds in general.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542292" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ISBI Practice Guidelines for Burn Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843629" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Dressings for superficial and partial thickness burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12358554" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Topical treatment of pediatric patients with burns: a practical guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19060725" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619933" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Benefit and harm of iodine in wound care: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2314091" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cytotoxicity to cultured human keratinocytes of topical antimicrobial agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/365175" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/365175" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20170497" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27126813" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/850849" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Topical chemotherapy for burns using cerium salts and silver sulfadiazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2216929" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outpatient management of burns in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281706" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Topical silver sulphadiazine--a new drug for ocular keratomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11164668" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955636" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cerium nitrate in the management of burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252266" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The use of cerium nitrate-silver sulphadiazine as a topical burns dressing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22842424" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns:  a multicenter, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7434206" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7019454" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A prospective analysis of silver sulfadiazine with and without cerium nitrate as a topical agent in the treatment of severely burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327800" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The role of Acticoat with nanocrystalline silver in the management of burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571738" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nanocrystalline silver: a systematic review of randomized trials conducted on burned patients and an evidence-based assessment of potential advantages over older silver formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11525858" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901734" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acticoat versus Allevyn as a split-thickness skin graft donor-site dressing: a prospective comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900600" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of donor-site healing under Xeroform and Jelonet dressings: unexpected findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537426" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management of skin-grafted burn wounds with Xeroform and layers of dry coarse-mesh gauze dressing results in excellent graft take and minimal nursing time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043238" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A simple cost-saving measure: 2.5% mafenide acetate solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26457099" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of Olea ointment and Acetate Mafenide on burn wounds - A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26360361" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Care of the Burn Casualty in the Prolonged Field Care Environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443125" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A prospective double-blinded comparative analysis of framycetin and silver sulphadiazine as topical agents for burns: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501103" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Five percent mafenide acetate solution in the treatment of thermal injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501103" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Five percent mafenide acetate solution in the treatment of thermal injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5576444" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mafenide acetate in burn treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5576444" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mafenide acetate in burn treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24290852" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Optimal treatment of partial thickness burns in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6391611" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25742878" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Honey as a topical treatment for wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27576926" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The effects of honey compared to silver sulfadiazine for the treatment of burns: A systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777856" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evidence-based decisions for local and systemic wound care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682580" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The use of povidone-iodine in superficial partial-thickness burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901735" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8290464" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Review of the use of povidone-iodine (PVP-I) in the treatment of burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effectiveness of 0.025% dakin's solution versus 1% silver sulphadiazine for treatment of partial thickness burns</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32241591" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: European consensus guidelines update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29456099" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Time to start putting down the knife: A systematic review of burns excision tools of randomised and non-randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24074719" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33388270" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Early experiences using bromelain-based enzymatic debridement in a tertiary burns centre in the United Kingdom: A retrospective case series review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28363663" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Enzymatic debridement of deeply burned faces: Healing and early scarring based on tissue preservation compared to traditional surgical debridement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35440290" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Enzymatic debridement: past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32445271" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rapid enzymatic burn debridement: A review of the paediatric clinical trial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32445271" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rapid enzymatic burn debridement: A review of the paediatric clinical trial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5326469" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Heterografts as biological dressings for large skin wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4582528" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of commercial porcine skin for wound dressings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004061" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Assessment of amniotic and polyurethane membrane dressings in the treatment of burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849850" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The role of allogenic amniotic membrane in burn treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24560801" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The clinical applications of human amnion in plastic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25876055" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Scientific and clinical support for the use of dehydrated amniotic membrane in wound management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23902526" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443516" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A critical evaluation of the use of Biobrane as a biologic skin substitute: a versatile tool for the plastic and reconstructive surgeon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258299" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Biobrane in the treatment of burn and scald injuries in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216512" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Suprathel, a new skin substitute, in the management of partial-thickness burn wounds: results of a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28557869" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A Prospective, Randomized, Controlled Trial Comparing the Outpatient Treatment of Pediatric and Adult Partial-Thickness Burns with Suprathel or Mepilex Ag.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19279675" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The search for an ideal temporary skin substitute: AWBAT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20361005" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : AWBAT: early clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349646" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Randomized controlled single center study comparing a polyhexanide containing bio-cellulose dressing with silver sulfadiazine cream in partial-thickness dermal burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3532390" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Therapeutic efficacy of Biobrane in partial- and full-thickness thermal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11988667" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A trial of the effectiveness of artificial dermis in the treatment of patients with burns greater than 45% total body surface area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3147806" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Biosynthetic compound dressings--management of hand burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2275770" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Immediate fascial flap reconstruction of joints and use of Biobrane in the burned limb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22365615" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A randomised prospective study of split skin graft donor site dressings: AWBAT-D™vs. Duoderm®.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21369369" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A Randomized, Prospective Study of the Treatment of Superficial Partial-Thickness Burns: AWBAT-S Versus Biobrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33320760" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Use of a biosynthetic wound dressing to treat burns: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5694367" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Successful control of burn-wound sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187754" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32725896" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Topical treatment for facial burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238345" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Topical silver for preventing wound infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24899251" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nonsilver treatment vs. silver sulfadiazine in treatment of partial-thickness burn wounds in children: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25909422" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : An open, parallel, randomized, comparative, multicenter investigation evaluating the efficacy and tolerability of Mepilex Ag versus silver sulfadiazine in the treatment of deep partial-thickness burn injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17825993" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Bioengineered skin substitutes for the management of burns: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12066030" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Wound colonization and infection: the role of topical antimicrobials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
